These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8162054)

  • 61. Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.
    Bliksrud YT; Brodtkorb E; Andresen PA; van den Berg IE; Kvittingen EA
    J Mol Med (Berl); 2005 May; 83(5):406-10. PubMed ID: 15759101
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fungal metabolic model for human type I hereditary tyrosinaemia.
    Fernández-Cañón JM; Peñalva MA
    Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9132-6. PubMed ID: 7568087
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I.
    Overturf K; al-Dhalimy M; Ou CN; Finegold M; Tanguay R; Lieber A; Kay M; Grompe M
    Hum Gene Ther; 1997 Mar; 8(5):513-21. PubMed ID: 9095403
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1.
    Bergeron A; D'Astous M; Timm DE; Tanguay RM
    J Biol Chem; 2001 May; 276(18):15225-31. PubMed ID: 11278491
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.
    Cassiman D; Zeevaert R; Holme E; Kvittingen EA; Jaeken J
    Orphanet J Rare Dis; 2009 Dec; 4():28. PubMed ID: 20003495
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Walking the ethical highwire: genetic screening and hereditary tyrosinemia.
    Romero R; Lavine JE
    Hepatology; 1995 Apr; 21(4):1193-5. PubMed ID: 7705795
    [No Abstract]   [Full Text] [Related]  

  • 67. Novel and recurrent tyrosine aminotransferase gene mutations in tyrosinemia type II.
    Hühn R; Stoermer H; Klingele B; Bausch E; Fois A; Farnetani M; Di Rocco M; Boué J; Kirk JM; Coleman R; Scherer G
    Hum Genet; 1998 Mar; 102(3):305-13. PubMed ID: 9544843
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Tyrosinemia].
    Salo MK
    Duodecim; 1992; 108(9):841-3. PubMed ID: 1366298
    [No Abstract]   [Full Text] [Related]  

  • 69. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
    Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
    Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
    [TBL] [Abstract][Full Text] [Related]  

  • 70. On the enzymic defects in hereditary tyrosinemia.
    Lindblad B; Lindstedt S; Steen G
    Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4641-5. PubMed ID: 270706
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.
    Dreumont N; Poudrier JA; Bergeron A; Levy HL; Baklouti F; Tanguay RM
    BMC Genet; 2001; 2():9. PubMed ID: 11476670
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Hypertyrosinemia].
    Endo F
    Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):529-31. PubMed ID: 3270860
    [No Abstract]   [Full Text] [Related]  

  • 73. Compound mutations (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type I in a Chinese patient.
    Cao YY; Zhang YL; DU J; Qu YJ; Zhong XM; Bai JL; Song F
    Chin Med J (Engl); 2012 Jun; 125(12):2132-6. PubMed ID: 22884142
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia.
    Demers SI; Russo P; Lettre F; Tanguay RM
    Hum Pathol; 2003 Dec; 34(12):1313-20. PubMed ID: 14691918
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of mutations (D128G, H141L) in the liver arginase gene of patients with hyperargininemia.
    Vockley JG; Tabor DE; Kern RM; Goodman BK; Wissmann PB; Kang DS; Grody WW; Cederbaum SD
    Hum Mutat; 1994; 4(2):150-4. PubMed ID: 7981719
    [No Abstract]   [Full Text] [Related]  

  • 76. Tyrosinaemia type I--an update.
    Kvittingen EA
    J Inherit Metab Dis; 1991; 14(4):554-62. PubMed ID: 1749221
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus.
    Klebig ML; Russell LB; Rinchik EM
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1363-7. PubMed ID: 1741389
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The enzyme defects in hereditary tyrosinaemia type I.
    Furukawa N; Hayano T; Sato N; Inoue F; Machida Y; Kinugasa A; Imashuku S; Kusunoki T; Takamatisu T
    J Inherit Metab Dis; 1984; 7 Suppl 2():137-8. PubMed ID: 6434869
    [No Abstract]   [Full Text] [Related]  

  • 79. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients.
    Arranz JA; Piñol F; Kozak L; Pérez-Cerdá C; Cormand B; Ugarte M; Riudor E
    Hum Mutat; 2002 Sep; 20(3):180-8. PubMed ID: 12203990
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia.
    Haber BA; Chuang E; Lee W; Taub R
    Hepatology; 1996 Jul; 24(1):65-71. PubMed ID: 8707285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.